ArticleTranslational gastroenterology and hepatology2026
Adverse reactions of second-line tyrosine kinase inhibitors in advanced hepatocellular carcinoma treatment: a descriptive analysis from WHO-VigiAccess.
Weifan Sui et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.